David S. Hong, MD | Authors


Larotrectinib Compared With Other TRK Inhibitors for TRK Fusion+ Lung Tumors

August 07, 2022

David S. Hong, MD, discusses the data supporting the use of larotrectinib for the treatment of TRK fusion-positive lung tumors. He also explains the difference between larotrectinib another FDA-approved TRK inhibitor, entrectinib.

EP. 4A: First -generation TRK Inhibitors and Treatment Resistance in NTRK Fusion-positive Cancers

April 27, 2022

In the third video interview of the series, David S. Hong, MD, from the University of Texas MD Anderson Cancer Center discusses the safety and efficacy of first-generation TRK inhibitors and reflects on challenges affecting next-generation TRK inhibitors including research into mechanisms of treatment resistance.